JAK2 and leukemia: JAK2 mutated clones were also described to show irregular growth trajectories [14] and JAK2 activation to contribute to PD-L1 expression [15], which may explain the response of JAK2 MRCH to graft-versus-leukemia effects and their relevance after HSCT without mac conditionings.